JP2023543670A - Ｍｙｃファミリー癌原遺伝子タンパク質のモジュレーター - Google Patents
Ｍｙｃファミリー癌原遺伝子タンパク質のモジュレーター Download PDFInfo
- Publication number
- JP2023543670A JP2023543670A JP2023513890A JP2023513890A JP2023543670A JP 2023543670 A JP2023543670 A JP 2023543670A JP 2023513890 A JP2023513890 A JP 2023513890A JP 2023513890 A JP2023513890 A JP 2023513890A JP 2023543670 A JP2023543670 A JP 2023543670A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heterocyclyl
- methyl
- group
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070762P | 2020-08-26 | 2020-08-26 | |
| US202063070753P | 2020-08-26 | 2020-08-26 | |
| US63/070,762 | 2020-08-26 | ||
| US63/070,753 | 2020-08-26 | ||
| PCT/US2021/047489 WO2022046861A1 (en) | 2020-08-26 | 2021-08-25 | Modulators of myc family proto-oncogene protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543670A true JP2023543670A (ja) | 2023-10-18 |
| JP2023543670A5 JP2023543670A5 (https=) | 2024-08-30 |
Family
ID=77775028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513890A Pending JP2023543670A (ja) | 2020-08-26 | 2021-08-25 | Ｍｙｃファミリー癌原遺伝子タンパク質のモジュレーター |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230322722A1 (https=) |
| EP (1) | EP4204411A1 (https=) |
| JP (1) | JP2023543670A (https=) |
| KR (1) | KR20230074733A (https=) |
| AU (1) | AU2021333760A1 (https=) |
| BR (1) | BR112023003517A2 (https=) |
| CA (1) | CA3190539A1 (https=) |
| IL (1) | IL300906A (https=) |
| MX (1) | MX2023002378A (https=) |
| TW (1) | TW202227411A (https=) |
| WO (1) | WO2022046861A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202325272A (zh) * | 2021-10-29 | 2023-07-01 | 日商田邊三菱製藥股份有限公司 | 新穎之螺環化合物 |
| US20250177393A1 (en) * | 2022-02-25 | 2025-06-05 | Nalo Therapeutics | Modulators of myc family proto-oncogene protein |
| WO2025043063A1 (en) * | 2023-08-24 | 2025-02-27 | Nalo Therapeutics, Inc. | Modulators of myc family proto-oncogene protein |
| WO2025043065A1 (en) * | 2023-08-24 | 2025-02-27 | Nalo Therapeutics, Inc. | Modulators of myc family proto-oncogene protein |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037814A1 (en) * | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| WO2007126126A1 (ja) * | 2006-04-27 | 2007-11-08 | Banyu Pharmaceutical Co., Ltd. | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| JP2008525422A (ja) * | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
| JP2008526759A (ja) * | 2004-12-30 | 2008-07-24 | エグゼリクシス， インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
| WO2020108516A1 (zh) * | 2018-11-27 | 2020-06-04 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
| WO2020172258A1 (en) * | 2019-02-19 | 2020-08-27 | Nalo Therapeutics | Modulators of myc family proto-oncogene protein |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070179125A1 (en) * | 2005-11-16 | 2007-08-02 | Damien Fraysse | Aminopyrimidines useful as kinase inhibitors |
| WO2010144522A1 (en) * | 2009-06-09 | 2010-12-16 | Abraxis Bioscience, Llc | Ureidophenyl substituted triazine derivatives and their therapeutical applications |
| CN103781779B (zh) * | 2011-09-05 | 2016-06-08 | 浙江海正药业股份有限公司 | 具有蛋白激酶抑制活性的4-取代-(3-取代-1h-吡唑-5-氨基)-嘧啶衍生物及其用途 |
| SG11202001706RA (en) * | 2017-10-27 | 2020-03-30 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| US11584737B2 (en) * | 2018-03-29 | 2023-02-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
-
2021
- 2021-08-25 CA CA3190539A patent/CA3190539A1/en active Pending
- 2021-08-25 KR KR1020237010219A patent/KR20230074733A/ko not_active Withdrawn
- 2021-08-25 JP JP2023513890A patent/JP2023543670A/ja active Pending
- 2021-08-25 EP EP21770396.6A patent/EP4204411A1/en not_active Withdrawn
- 2021-08-25 BR BR112023003517A patent/BR112023003517A2/pt not_active Application Discontinuation
- 2021-08-25 MX MX2023002378A patent/MX2023002378A/es unknown
- 2021-08-25 IL IL300906A patent/IL300906A/en unknown
- 2021-08-25 WO PCT/US2021/047489 patent/WO2022046861A1/en not_active Ceased
- 2021-08-25 AU AU2021333760A patent/AU2021333760A1/en not_active Abandoned
- 2021-08-25 US US18/023,298 patent/US20230322722A1/en active Pending
- 2021-08-26 TW TW110131640A patent/TW202227411A/zh unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004037814A1 (en) * | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| JP2008525422A (ja) * | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | 抗癌剤として有用な複素芳香族誘導体 |
| JP2008526759A (ja) * | 2004-12-30 | 2008-07-24 | エグゼリクシス， インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
| WO2007126126A1 (ja) * | 2006-04-27 | 2007-11-08 | Banyu Pharmaceutical Co., Ltd. | オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体 |
| WO2020108516A1 (zh) * | 2018-11-27 | 2020-06-04 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
| WO2020172258A1 (en) * | 2019-02-19 | 2020-08-27 | Nalo Therapeutics | Modulators of myc family proto-oncogene protein |
Non-Patent Citations (1)
| Title |
|---|
| CRAWFORD, JAMES J. ET AL.: ""Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 12, JPN6025036258, 12 June 2015 (2015-06-12), pages 5121 - 5136, ISSN: 0005807612 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230074733A (ko) | 2023-05-31 |
| MX2023002378A (es) | 2023-05-22 |
| IL300906A (en) | 2023-04-01 |
| AU2021333760A1 (en) | 2023-04-06 |
| CA3190539A1 (en) | 2022-03-03 |
| BR112023003517A2 (pt) | 2023-05-09 |
| US20230322722A1 (en) | 2023-10-12 |
| WO2022046861A1 (en) | 2022-03-03 |
| TW202227411A (zh) | 2022-07-16 |
| EP4204411A1 (en) | 2023-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3761980B1 (en) | Amino acid compounds and methods of use | |
| KR102049534B1 (ko) | 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법 | |
| JP6096219B2 (ja) | キナーゼ阻害剤として有用なトリアゾリルまたはトリアジアゾリル置換されたピリジル化合物 | |
| JP2023543670A (ja) | Ｍｙｃファミリー癌原遺伝子タンパク質のモジュレーター | |
| AU2016360481A1 (en) | Novel biphenyl compound or salt thereof | |
| JP2015503620A (ja) | キナーゼ阻害剤として有用な複素環置換されたピリジル化合物 | |
| KR20160027992A (ko) | Ｒａｆ 카나아제 억제제로서 유용한 화합물 | |
| IL298760A (en) | Fibroblast growth factor receptor kinase inhibitors | |
| US20210369710A1 (en) | Modulators of myc family proto-oncogene protein | |
| IL302837A (en) | Aryl derivatives for treating trpm3 mediated disorders | |
| JP7064495B2 (ja) | ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体 | |
| US20190152992A1 (en) | Benzodioxane derivatives and their pharmaceutical use | |
| US20220370431A1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| US12570655B2 (en) | Cysteine covalent modifiers of AKT1 and uses thereof | |
| CN116322692A (zh) | 自分泌运动因子抑制剂化合物 | |
| EP4463452B1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| CN116490499A (zh) | Myc家族原癌基因蛋白的调节剂 | |
| WO2021194982A1 (en) | Potent and selective irreversible inhibitors of irak1 | |
| HK40063870A (en) | Modulators of myc family proto-oncogene protein | |
| HK40097285A (zh) | Myc家族原癌基因蛋白的调节剂 | |
| KR20190132703A (ko) | 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법 | |
| HK1262487A1 (en) | Bicyclic heteroaryl derivatives | |
| HK1262487B (en) | Bicyclic heteroaryl derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230911 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240822 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240822 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250828 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250901 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260303 |